Falciparum malaria treated with a fixed combination of mefloquine, sulfadoxine and pyrimethamine: a field study in adults in Burma. 1985

F Tin, and N Hlaing, and T Tun, and S Win, and R Lasserre

In a field study conducted in Burma, 54 semi-immune adults suffering from falciparum malaria (mean parasite count, 15 328/mm(3) before treatment) were given a single dose of a fixed combination of 750 mg mefloquine base, 1500 mg sulfadoxine, and 75 mg pyrimethamine (3 tablets of Fansimef). All these patients were cleared of asexual parasites by day 7, giving a cure rate of 100%; the mean clearance time was 2.6 days. Reappearance of parasitaemia occurred in 10 patients on or before day 7 and persisted for one day in 8 of them and for two days in 2 patients. It eventually disappeared without further treatment. No recrudescence occurred during the follow-up time of four weeks despite the fact that there was active transmission of Plasmodium falciparum in the area throughout the whole of the study period. The drug was generally well tolerated, though mild to moderate giddiness was reported by 49 patients (90.7%) and severe giddiness by 3 patients (5.5%). Nausea occurred in 25 patients (46.3%) and vomiting in 17 (31.5%).

UI MeSH Term Description Entries
D008288 Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Marsh Fever,Plasmodium Infections,Remittent Fever,Infections, Plasmodium,Paludism,Fever, Marsh,Fever, Remittent,Infection, Plasmodium,Plasmodium Infection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D011739 Pyrimethamine One of the FOLIC ACID ANTAGONISTS that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. Chloridin,Daraprim,Malocide,Tindurine
D011804 Quinolines
D002052 Myanmar A republic of southeast Asia, northwest of Thailand, long familiar as Burma. Its capital is Yangon, formerly Rangoon. Inhabited by people of Mongolian stock and probably of Tibetan origin, by the 3d century A.D. it was settled by Hindus. The modern Burmese state was founded in the 18th century but was in conflict with the British during the 19th century. Made a crown colony of Great Britain in 1937, it was granted independence in 1947. In 1989 it became Myanmar. The name comes from myanma, meaning the strong, as applied to the Burmese people themselves. (From Webster's New Geographical Dictionary, 1988, p192 & Room, Brewer's Dictionary of Names, 1992, p367) Burma,Myanma
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females

Related Publications

F Tin, and N Hlaing, and T Tun, and S Win, and R Lasserre
January 1987, Bulletin of the World Health Organization,
F Tin, and N Hlaing, and T Tun, and S Win, and R Lasserre
January 1985, Lancet (London, England),
F Tin, and N Hlaing, and T Tun, and S Win, and R Lasserre
March 1985, Lancet (London, England),
F Tin, and N Hlaing, and T Tun, and S Win, and R Lasserre
May 1990, BMJ (Clinical research ed.),
F Tin, and N Hlaing, and T Tun, and S Win, and R Lasserre
September 1985, Lancet (London, England),
F Tin, and N Hlaing, and T Tun, and S Win, and R Lasserre
January 1979, Bulletin of the World Health Organization,
F Tin, and N Hlaing, and T Tun, and S Win, and R Lasserre
December 1984, Lancet (London, England),
F Tin, and N Hlaing, and T Tun, and S Win, and R Lasserre
January 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene,
F Tin, and N Hlaing, and T Tun, and S Win, and R Lasserre
January 1990, Bulletin of the World Health Organization,
F Tin, and N Hlaing, and T Tun, and S Win, and R Lasserre
January 1985, Bulletin of the World Health Organization,
Copied contents to your clipboard!